Patent disclosure and R&D competition in pharmaceuticals

Economics of Innovation and New Technology

Volumn 18, Issue 5, 2009, Pages 467-486

  Magazzini, Laura ^a   Pammolli, Fabio ^b,c   Riccaboni, Massimo ^d   Rossi, Maria Alessandra ^e  

^a UNIVERSITY OF VERONA   (Italy)

^b IMT SCHOOL FOR ADVANCED STUDIES LUCCA   (Italy)

^c Fondazione CERM   (Italy)

^d UNIVERSITY OF TRENTO   (Italy)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

Innovation; Patent disclosure; R D competition

Indexed keywords

EID: 70450058373     PISSN: 10438599     EISSN: 14768364     Source Type: Journal    
DOI: 10.1080/10438590802547183     Document Type: Article

References (50)

1. Alcacer, J., and M. Gittelman, 2006. Patent citations as a measure of knowledge flows: The influence of examiner citations. The Review of Economics and Statistics 88, no. 4: 774-9.
2. Anton, J., and D. Yao. 2003. Patents, invalidity, and the strategic transmission of enabling information. Journal of Economics & Management Strategy 12, no. 2: 151-78.
3. Arora, A., A. Gambardella, and A. Fosfuri. 2001. Markets for technology:The economics of innovation and corporate strategy. Cambridge, MA: The MIT Press.
4. Arrow, K. 1962. Economic welfare and the allocation of resources for invention. In The rate and direction of inventive activity: Economic and social factors, ed. R. Nelson, 609-26. Princeton, NJ: Princeton University Press.
5. Baker, S., D. Lichtman, and C. Mezzetti. 2005. Disclosure and investment as strategies in the patent race. Journal of Law and Economics 48: 173-94.
6. Bessen, J. 2005. Patents and the diffusion of technical information. Economics Letters 86, no. 1: 121-28.
7. Chan, A.-W., A. Hrobjartsson, M. Haahr, P. Gotzsche, and D. Altman. 2004. Empirical evidence for selective reporting of outcomes in randomized trials. JAMA 291, no. 20: 2457-65.
8. Cohen, W., R. Nelson, and J. Walsh. 2000. Protecting their intellectual assets: Appropriability conditions and why US manufacturing firms patent (or not). NBER Working Paper No. 7552.
9. Dallavalle, S., L. Merlini, S. Penco, and F. Zunino. 2002. Perspective in camptothecin development. Expert Opinion on Therapeutic Patents 12: 837-44.
10. David, P., D. Mowery, and E. Steinmuller. 1992. Analyzing the economic payoffs from basic research. Economics of Innovation and New Technology 2: 73-90.
11. DiMasi, J. 1995. Success rates for new drugs entering clinical testing in the United States. Clinical Pharmacology & Therapeutics 58, no. 1: 1-14.
12. Gaestel, M., A. Kotlyarov, and M. Kracht. 2009. Targeting innate immunity protein kinase signalling in inflammation. Nature Reviews Drug Discovery 8: 480-99.
13. Gambardella, A. 1995. Science and innovation: The US pharmaceutical industry in the 1980s. Cambridge, UK: Cambridge University Press.
14. Grabowski, H., J. Vernon, and J. DiMasi. 2002. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 20, no. 3: 11-29.
15. Hall, B., A. Jaffe, and M. Trajtenberg. 2001. The NBER patent citation data file: Lessons, insights and methodological tools. NBER Working Paper No. 8498.
16. Harhoff, D., F. Narin, F. Scherer, and K. Vopel. 1999. Citation frequency and the value of patented inventions. The Review of Economics and Statistics 81, no. 3: 511-15.
17. Heller, M., and R. Eisenberg. 1998. Can patent deter innovation? The anti-commons in biomedical research. Science 280: 698-701.
18. Henderson, R., and I. Cockburn. 1996. Scale, scope, and spillovers: The determinants of research productivity in drug discovery. RAND Journal of Economics 27, no. 1: 32-59.
19. Henderson, R., L. Orsenigo, and G. Pisano. 1999. The pharmaceutical industry and the revolution in molecolar biology: Exploring the interactions between scientific, institutional and organizational change. In Sources of industrial leadership, ed. D. Mowery and R. Nelson, 267-311. Cambrigde, MA: Cambridge University Press.
20. Horstmann, I., G. MacDonald, and A. Slivinski. 1985. Patents as information transfer mecha-nisms: To patent or (maybe) not to patent. The Journal of Political Economy 93, no. 5: 837-58.
21. Hsiang, Y., R. Hertzberg, S. Hecht, and L. Liu. 1985. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. The Journal of Biological Chemistry 260, no. 27: 14873-8.
22. Jaffe, A., and M. Trajtenberg. 1996. Flows of knowledge from universities and federal labs: Modeling the flow of patent citations over time and across institutional and geographic boundaries. NBER Working Paper No. 5712.
23. Jaffe, A., and M. Trajtenberg. 2002. Patents, citations and innovations: A window on the knowledge economy. Cambridge, MA: The MIT Press.
24. Jaffe, A., M. Trajtenberg, and M. Fogarty. 2000. The meaning of patent citations: Report on the NBER/Case-Western Reserve Survey of Patentees. NBER Working Paper No. 7631.
25. Janis, M. 2000. On courts herding cats: Contending with the written description requirement (and other unruly patent disclosure doctrines). Washington University Journal of Law and Policy 2: 55-108.
26. Johnson, R., and K. Dickersin. 2007. Publication bias against negative results from clinical trials: Three of the seven deadly sins. Nature Clinical Practice Neurology 3, no. 11: 590-1.
27. Landes, W., and R. Posner. 2003. The economic structure of intellectual property law. MA: Belknap Press of Harvard University Press Cambridge.
28. Lanjouw, J., and M. Schankerman. 1999. The quality of ideas: Measuring innovation with multiple indicators. NBER Working Paper No. 7345.
29. Lee, J., J. Laydon, P. McDonnell, T. Gallagher, S. Kumar, D. Green, and D. McNulty. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, no. 6508: 739-46.
30. Levin, R., A. Klevorick, R. Nelson, S. Winter, R. Gilbert, and Z. Griliches. 1987. Appropriating the returns from industrial research and development. Brookings Papers on Economic Activity. Microeconomics 3: 783-831.
31. Lichtman, D., S. Baker, and K. Kraus. 2000. Strategic disclosure in the patent system. Vanderbilt Law Review 53: 2175-217.
32. Machlup, F., and E. Penrose. 1950. The patent controversy in the nineteenth century. The Journal of Economic History 10, no. 1: 1-29.
33. Mansfield, E. 1986. Patents and innovation: An empirical study. Management Science 32, no. 2: 173-81.
34. Mervis, J. 2005. Productivity counts - But the definition is key. Science 309, no. 5735: 726-7.
35. Murray, F., and S. Stern. 2007. Do formal intellectual property rights hinder the free flow of scientific knowledge? An empirical test of the anti-commons hypothesis. Journal of Economic Behavior and Organization 63, no. 4: 648-87.
36. Oppenheim, C. 1998. How SMEs use the patent literature. Summary Report for the UK Economic and Social Research Council.
37. Oprea, T., A. Davis, S. Teague, and P. Leeson. 2001. Is there a difference between leads and drugs? A historical perspective. Journal of Chemical Information and Computer Sciences 41, no. 5: 1308-15.
38. Orsenigo, L., F. Pammolli, and M. Riccaboni. 2001. Technological change and network dynamics: Lessons from the pharmaceutical industry. Research Policy 30, no. 3: 485-508.
39. Pammolli, F. 1996. Innovazione, Concorrenza e Strategie di Sviluppo nell'Industria Farmaceutica. Milan: Guerini Scientifica.
40. Parchomovsky, G. 2000. Publish or perish. Michigan Law Review 98, no. 4: 926-52.
41. Plant, A. 1934. The economic theory concerning patents for inventions. In Selected economic essays and addresses, 35-6. London: Routledge & Kegan Paul.
42. Reichman, J. 1995. Universal minimum standards of intellectual property protection under the TRIPS component of the WTO agreement. International Lawyer 29: 345-88.
43. Scotchmer, S., and J. Green. 1990. Novelty and disclosure in patent law. The RAND Journal of Economics 21, no. 1: 131-46.
44. Sutton, J. 1998. Technology and market structure: Theory and history. MA: The MIT Press Cambridge.
45. Tang, P., J. Adams, and D. Pare. 2001. Patent protection of computer programmes. Report Submitted to the European Commission - Directorate-General Enterprise.
46. Trajtenberg, M. 1990. A penny for your quotes: Patent citations and the value of innovations. The RAND Journal of Economics 21, no. 1: 172-87.
47. Trajtenberg, M., R. Henderson, and A. Jaffe. 1997. University vs. corporate patents: A window on the Basicness of innovations. Economics of Innovation and New Technology 5, no. 1: 19-50.
48. Wall, M., M. Wani, C. Cook, K. Palmer, A. McPhail, and G. Sim. 1966. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata 1, 2. Journal of the American Chemical Society 88, no. 16, 3888-90.
49. WHO. 2006. Public health: Innovation and intellectual property rights. Geneva, Switzerland: World Health Organization.
50. Zarin, A., and T. Tse. 2008. Moving toward transparency of clinical trials. Science 319, no. 5868: 1340-2.